Oncoinvent AS has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study of Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer. The company is optimistic about the potential of Radspherin® and plans to advance its clinical development. The phase 1/2a clinical trials have shown that Radspherin® is well tolerated, and a recommended dose has been selected. The planned phase 2b trial, set to start in Q2 2024, will compare the efficacy and safety of Radspherin® with standard treatments for colorectal carcinoma.
Frequently Asked Questions
Q: What is the announcement made by Oncoinvent?
A: Oncoinvent announced the U.S. FDA clearance of their Investigational New Drug (IND) application for Radspherin in colorectal cancer patients.
Q: What is Radspherin?
A: Radspherin is a therapy being developed by Oncoinvent for the treatment of solid cancers.
Q: When was the FDA clearance announcement made?
A: The FDA clearance announcement was made recently, approximately 9 hours ago.
Q: Where can I find more information about Oncoinvent's annual report?
A: You can find more information about Oncoinvent's annual report on their official website. Here is the link to their Annual Report 2022: link
Q: Is there a clinical trial related to Radspherin in colorectal carcinoma subjects?
A: Yes, there is a clinical trial related to Radspherin in colorectal carcinoma subjects. You can find more information about it on the ClinicalTrials.gov website. Here is the link to the study: link